There’s a famous quote by Friedrich Nietzsche that says “That which does not kill us makes us stronger.” I have follicular ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

Phase Ib/IIa clinical trial of IMM0306, a bispecific molecule for treating indolent lymphoma. The trial demonstrated an 84% overall response rate in follicular lymphoma patients, with a 100% rate in ...

Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...